ABVC BioPharma, Inc. (ABVC) stock
ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
$0.96−0.03 (-3.03%)
Close on Nov 12, 2026Market cap $25.59MP/E –Yield –
ABVC BioPharma r&d expenses
Research and development expenses are spending on new products and technology.
ABVC BioPharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $102.91K, down 17.0% year over year. For fiscal 2025 it was $121.09K, down 32.5% from the year before. The highest annual figure on record is $10.00M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.09K | -32.5% |
| FY2024 | Dec 31, 2024 | $179.27K | -83.1% |
| FY2023 | Dec 31, 2023 | $1.06M | -60.5% |
| FY2022 | Dec 31, 2022 | $2.69M | +168.3% |
| FY2021 | Dec 31, 2021 | $1.00M | +82.6% |
| FY2020 | Dec 31, 2020 | $549.66K | -47.6% |
| FY2019 | Dec 31, 2019 | $1.05M | -66.7% |
| FY2017 | Sep 30, 2017 | $3.15M | -68.5% |
| FY2016 | Sep 30, 2016 | $10.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $18.04K | -39.6% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $22.71K | -31.8% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $33.10K | +14.7% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $29.06K | -9.1% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $29.89K | -21.0% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $33.28K | -17.6% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $28.86K | -58.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $31.98K | -55.7% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $37.83K | -73.2% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $40.40K | -92.1% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $69.07K | -79.4% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $72.19K | -95.2% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $141.31K | -53.7% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $514.44K | -3.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $334.98K | -6.8% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $1.50M | +474.9% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $305.48K | +16.0% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $532.78K | +48.5% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $359.40K | +196.3% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $260.19K | +42.0% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $263.42K | +95.9% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $358.88K | +158.0% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $121.32K | +30.7% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $183.28K | -32.0% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $134.50K | -50.0% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $139.08K | +58.5% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $92.79K | -78.0% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $269.59K | -91.3% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $269.24K | +1438.5% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $87.77K | +249.0% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $421.96K | +1574.6% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $3.08M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $17.50K | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $25.15K | -99.6% |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $25.20K | -99.3% |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $0 | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $0 | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | $6.50M | – |
| Q1 FY2016CQ4 2015 | Dec 31, 2015 | $3.50M | – |
See a number that looks wrong?